Welcome to our dedicated page for Molecular Templates news (Ticker: MTEM), a resource for investors and traders seeking the latest updates and insights on Molecular Templates stock.
Molecular Templates Inc (MTEM:NASDAQ) is a clinical-stage biopharmaceutical company pioneering engineered toxin body (ETB) therapies for cancer treatment. This page provides investors and industry observers with timely updates on MTEM’s clinical developments, strategic partnerships, and corporate milestones.
Access the latest press releases, clinical trial results, and regulatory filings in one centralized location. Our curated collection includes updates on MTEM’s ETB platform advancements, oncology research collaborations, and financial disclosures. Key areas of coverage include phase trial progress, intellectual property developments, and executive leadership announcements.
Bookmark this page to efficiently track MTEM’s progress in developing targeted cancer therapies. For stakeholders monitoring immuno-oncology innovations, this resource offers organized access to verified company updates without promotional bias. Check regularly for new developments in MTEM’s mission to address unmet needs in oncology through its proprietary therapeutic platform.
Molecular Templates (MTEM) reported fourth quarter 2020 financial results, highlighting significant advancements in its clinical pipeline, including collaborations and funding. The company has four clinical-stage programs, with MT-5111 targeting HER2 and TAK-169 targeting CD38 in partnership with Takeda. MTEM secured a $70 million upfront payment from Bristol Myers Squibb for a strategic collaboration and raised $75.9 million through an equity offering. However, the net loss increased to $28.4 million from $15.9 million year-over-year, with revenues declining to $3.5 million.
Molecular Templates (Nasdaq: MTEM) announced its participation in three major healthcare conferences: the Cowen 41st Annual Health Care Conference, Barclays Global Healthcare Conference, and Oppenheimer 31st Annual Healthcare Conference. The Cowen conference is scheduled for March 1-4, with a presentation on March 4 at 11:10 AM ET. The Barclays conference runs from March 9-11, featuring a presentation on March 10 at 3:00 PM ET. The Oppenheimer conference takes place March 16-17, with a presentation on March 17 at 11:20 AM ET. Webcasts will be accessible via MTEM's website.
Molecular Templates (Nasdaq: MTEM) announced a public offering of 6,000,000 shares at $12.65 per share, aiming to raise approximately $75.9 million in gross proceeds. The offering is expected to close around February 22, 2021, subject to customary conditions. The proceeds will fund Phase II clinical studies for MT-3724, ongoing studies for MT-5111, and development expenses in collaboration with Takeda, among other expenses. The underwriters have a 30-day option to purchase up to 900,000 additional shares.
Molecular Templates (MTEM) has initiated an underwritten public offering of its common stock, with the potential for underwriters to purchase an additional 15% of shares. The funds raised will support Phase II and Phase I clinical studies for its targeted cancer therapies, including MT-3724 and MT-5111, and development costs associated with collaborations, particularly with Takeda. The offering is contingent upon market conditions, and full details will be filed with the SEC.
Molecular Templates (Nasdaq: MTEM) has secured a $70 million upfront payment from Bristol Myers Squibb as part of a strategic research collaboration aimed at discovering and developing novel therapies for oncology targets. The collaboration will leverage MTEM's engineered toxin body (ETB) platform, which focuses on targeted cancer treatments. MTEM may also receive up to $1.3 billion in additional milestone payments, alongside tiered royalties on future sales, enhancing its financial outlook significantly.
Molecular Templates (Nasdaq: MTEM) announced that the FDA accepted its IND application for MT-6402, a next-generation engineered toxin body aimed at PD-L1-positive cancers. The company plans to initiate a Phase 1 study in relapsed/refractory patients with PD-L1-positive solid tumors in 2Q21. MT-6402 employs dual mechanisms to induce an immune response against tumors. The study will include dose escalation and expansion cohorts to evaluate the efficacy of MT-6402 as a monotherapy. Updates on the trial are expected by the end of 2021.
Molecular Templates (MTEM) announced progress in the Phase 1 study of MT5111, a HER2-targeted engineered toxin body (ETB), with 16 subjects treated and successful completion of five dosing cohorts. Pharmacokinetic data suggests that doses ≥5.0 μg/kg may be necessary for efficacy. No dose-limiting toxicities have been reported, and the most common adverse events were mild. The company plans to initiate a HER2 positive breast cancer expansion cohort in 1H21 at a dose of 10 μg/kg. The safety profile encourages further exploration of MT5111’s potential in overcoming resistance in HER2-positive cancers.
Molecular Templates (Nasdaq: MTEM) announced its participation in several upcoming healthcare conferences, including the Stifel 2020 Virtual Healthcare Conference and the Evercore ISI HealthCONx Conference. The Stifel conference will take place from November 16-18, with a presentation on November 17 at 9:20 am ET. The Evercore conference is scheduled for December 1-3, featuring a presentation on December 3 at 10:05 am ET. Live webcasts and presentations will be accessible through the company’s website.
Molecular Templates (Nasdaq: MTEM) reported its Q3 2020 financial results, highlighting a net loss of $23.2 million or $0.47 per share, improved from a loss of $38.2 million in Q3 2019. Revenues increased to $4.3 million, up from $3.6 million, driven by collaborative agreements. However, the FDA placed MT-3724 clinical studies on partial clinical hold after a treatment-related fatality due to capillary leak syndrome. Current patients can continue dosing, but no new enrollments will take place until the hold is lifted. Cash reserves of $118.2 million are projected to sustain operations into H2 2022.
Molecular Templates reported Q2 2020 financial results, showing a net loss of $31.2 million, or $0.68 per share, compared to a loss of $9.2 million in Q2 2019. Revenue increased to $6.9 million from $5.4 million year-over-year. The company secured a $45 million debt facility and raised $50 million via an ATM. Molecular Templates is advancing multiple ETB programs, with interim data expected in H2 2020 for MT-3724 and MT-5111. Challenges from COVID-19 have slowed patient enrollment in trials, but manufacturing operations remain uninterrupted.
